MiNK-215 eliminated MSS colorectal cancer liver metastases in human organoid models
MiNK-215 exhibits potent anti-tumor activity through multiple mechanisms including immune activation
April 08, 2024 -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases, today announced the p